Edgewise Therapeutics (EWTX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Edgewise Therapeutics (EWTX)
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
Key Insights
Critical company metrics and information
Share Price
$32.59Market Cap
$3.09 BillionTotal Outstanding Shares
94.69 Million SharesTotal Employees
108Dividend
No dividendIPO Date
March 26, 2021SIC Description
Pharmaceutical PreparationsHomepage
https://www.edgewisetx.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow | $11.85 Million |
| Net Cash Flow From Operating Activities, Continuing | $-108.90 Million |
| Net Cash Flow, Continuing | $11.85 Million |
| Net Cash Flow From Financing Activities | $299.35 Million |
| Net Cash Flow From Financing Activities, Continuing | $299.35 Million |
| Net Cash Flow From Investing Activities | $-178.59 Million |
| Net Cash Flow From Operating Activities | $-108.90 Million |
| Net Cash Flow From Investing Activities, Continuing | $-178.59 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Diluted Average Shares | $91.99 Million |
| Revenues | $0.00 |
| Operating Expenses | $147.15 Million |
| Net Income/Loss | $-124.29 Million |
| Research and Development | $118.28 Million |
| Basic Earnings Per Share | $1.50 |
| Operating Income/Loss | $-147.15 Million |
| Other Operating Expenses | $28.87 Million |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Income/Loss From Continuing Operations After Tax | $-124.29 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-124.29 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Net Income/Loss Attributable To Parent | $-124.29 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Income/Loss From Continuing Operations Before Tax | $-124.29 Million |
| Basic Average Shares | $91.99 Million |
| Diluted Earnings Per Share | $1.50 |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Wages | $6.18 Million |
| Liabilities And Equity | $511.28 Million |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $488.88 Million |
| Assets | $511.28 Million |
| Noncurrent Assets | $11.85 Million |
| Fixed Assets | $9.97 Million |
| Other Current Liabilities | $7.12 Million |
| Noncurrent Liabilities | $3.45 Million |
| Other Non-current Assets | $1.88 Million |
| Liabilities | $22.41 Million |
| Equity | $488.88 Million |
| Accounts Payable | $5.65 Million |
| Current Assets | $499.44 Million |
| Current Liabilities | $18.96 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.